Weight Management

 
Exercise Plus GLP-1 RA May Preserve BMD During Weight Loss, Study Finds
July 03, 2024

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

5 Questions on the ADA 2024 Standards of Care in Diabetes
June 26, 2024

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
June 24, 2024

ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.

USPSTF Recommends Intensive Behavioral Interventions for Children, Teens with High BMI
June 21, 2024

The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.

WHO Issues Medical Product Alert for Counterfeit Semaglutide
June 21, 2024

Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.

ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar
June 20, 2024

Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.

ADA Standards of Care in Diabetes 2024: A Guideline Topline
June 19, 2024

For primary care clinicians, this Guideline Topline provides a summary of 2024 ADA Standard of Care updates that may support improved outcomes in your practice.

ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care
June 17, 2024

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose
June 17, 2024

Your daily dose of the clinical news you may have missed.

Tirzepatide Found Superior to Placebo in MASH Resolution, Fibrosis Improvement
June 13, 2024

More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.